These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 25543114)

  • 1. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
    Lo TF; Hsieh CR
    J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan.
    Liu YM; Hsieh CR
    Health Econ; 2012 May; 21(5):496-513. PubMed ID: 21394819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of expanded mental health benefits on treatment costs.
    Sasso AT; Lurie IZ; Lee JU; Lindrooth RC
    J Ment Health Policy Econ; 2006 Mar; 9(1):25-33. PubMed ID: 16733269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An examination of Alzheimer's disease case definitions using Medicare claims and survey data.
    Lin PJ; Kaufer DI; Maciejewski ML; Ganguly R; Paul JE; Biddle AK
    Alzheimers Dement; 2010 Jul; 6(4):334-41. PubMed ID: 20434960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective?
    Hsieh CR; Sloan FA
    Value Health; 2008; 11(2):334-44. PubMed ID: 18380646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009.
    Lichtenberg FR
    Econ Hum Biol; 2014 Mar; 13():107-27. PubMed ID: 23664114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
    Rice DP; Fillit HM; Max W; Knopman DS; Lloyd JR; Duttagupta S
    Am J Manag Care; 2001 Aug; 7(8):809-18. PubMed ID: 11519239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical management, costs, and consequences of Alzheimer's disease in Germany: an analysis of health claims data.
    Brüggenjürgen B; Andersohn F; Ezzat N; Lacey L; Willich S
    J Med Econ; 2015 Jun; 18(6):466-73. PubMed ID: 25692902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of donepezil therapy on health costs in a Medicare managed care plan.
    Hill JW; Futterman R; Mastey V; Fillit H
    Manag Care Interface; 2002 Mar; 15(3):63-70. PubMed ID: 11925682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term persistence of high health care costs in a nationally representative sample of children.
    Liptak GS; Shone LP; Auinger P; Dick AW; Ryan SA; Szilagyi PG
    Pediatrics; 2006 Oct; 118(4):e1001-9. PubMed ID: 17015496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population.
    Geldmacher DS; Kirson NY; Birnbaum HG; Eapen S; Kantor E; Cummings AK; Joish VN
    Appl Health Econ Health Policy; 2013 Aug; 11(4):407-13. PubMed ID: 23700254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
    Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
    Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of proximity to death in modelling community medication expenditures for older people: evidence from New Zealand.
    Moore PV; Bennett K; Normand C
    Appl Health Econ Health Policy; 2014 Dec; 12(6):623-33. PubMed ID: 25141830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.
    Chen LC; Schafheutle EI; Noyce PR
    Res Social Adm Pharm; 2009 Sep; 5(3):211-24. PubMed ID: 19733822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of cognitive enhancers and associated medical care costs among patients with dementia: a nationwide study in Taiwan.
    Ku LJ; Pai MC
    Int Psychogeriatr; 2014 May; 26(5):795-804. PubMed ID: 24429098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan.
    Liu YM; Yang YH; Hsieh CR
    Soc Sci Med; 2011 Mar; 72(6):919-27. PubMed ID: 21333432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.